Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG–positive patients

Annals of Neurology

Volumn 82, Issue 1, 2017, Pages 79-92

  Gadoth, Avi ^a   Pittock, Sean J ^a   Dubey, Divyanshu ^a   McKeon, Andrew ^a   Britton, Jeff W ^a   Schmeling, John E ^a   Smith, Aurelia ^a   Kotsenas, Amy L ^a   Watson, Robert E ^a   Lachance, Daniel H ^a   Flanagan, Eoin P ^a   Lennon, Vanda A ^a   Klein, Christopher J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AUTOANTIBODY; CASPR 2 PROTEIN; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LEVETIRACETAM; LGI 1 PROTEIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NARCOTIC AGENT; PREGABALIN; PRIMIDONE; PROTEIN; UNCLASSIFIED DRUG; VGKC PROTEIN; VOLTAGE GATED POTASSIUM CHANNEL; CNTNAP2 PROTEIN, HUMAN; LGI1 PROTEIN, HUMAN; MEMBRANE PROTEIN; NERVE PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOSIS; AUDITORY HALLUCINATION; AUTOIMMUNITY; BASAL GANGLION; BEHAVIOR CHANGE; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL OUTCOME; COGNITIVE DEFECT; DISEASE ASSOCIATION; DIZZINESS; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; HEAD INJURY; HUMAN; IMMUNOPRECIPITATION; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEMORY TEST; MYOCLONUS; NEOPLASM; NEUROLOGIC DISEASE; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAROXYSMAL DIZZINESS SPELL; PERIPHERAL NEUROPATHY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANKIN SCALE; SEIZURE; SEROPREVALENCE; SIMPLE PARTIAL SEIZURE; SODIUM BLOOD LEVEL; THYMOMA; VERTIGO; VERY ELDERLY; AGE; DISABILITY; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; MINNESOTA; NEUROIMAGING; PAIN; PHENOTYPE; SEIZURES, FEBRILE; SEROEPIDEMIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROSPINAL FLUID; DISABILITY EVALUATION; DIZZINESS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MINNESOTA; NEOPLASMS; NERVE TISSUE PROTEINS; NEUROIMAGING; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; PHENOTYPE; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEINS; SEIZURES, FEBRILE; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 85025592082     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24979     Document Type: Article

References (36)

1. Shillito P, Molenaar PC, Vincent A, et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann Neurol 1995;38:714–722.
2. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 1997;41:238–246.
3. Knowles CH, Lang B, Clover L, et al. A role for autoantibodies in some cases of acquired non-paraneoplastic gut dysmotility. Scand J Gastroenterol 2002;37:166–170.
4. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004;127(pt 3):701–712.
5. Jacob S, Irani SR, Rajabally YA, et al. Hypothermia in VGKC antibody-associated limbic encephalitis. J Neurol Neurosurg Psychiatry 2008;79:202–204.
6. Tan KM, Lennon VA, Klein CJ, et al. Clinical spectrum of voltage gated potassium channel autoimmunity. Neurology 2008;70:1883–1890.
7. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133:2734–2748.
8. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011;69:303–311.
9. Klein CJ, Lennon VA, Aston PA, et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 2013;70:229–234.
10. van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 2016;87:1449–1456.
11. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010;9:776–785.
12. Arino H, Armangue T, Petit-Pedrol M, et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016;87:759–765.
13. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:892–900.
14. Laurencin C, Andre-Obadia N, Camdessanche JP, et al. Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. Neurology 2015;85:2076–2078.
15. van Sonderen A, Arino H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016;87:521–528.
16. Klein CJ, Lennon VA, Aston PA, et al. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012;79:1136–1144.
17. Lahoria R, Pittock SJ, Gadoth A, et al. Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy. Muscle Nerve 2017;55:520–525.
18. Sirerol-Piquer MS, Ayerdi-Izquierdo A, Morante-Redolat JM, et al. The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the cell surface. Hum Mol Genet 2006;15:3436–3445.
19. Schulte U, Thumfart JO, Klocker N, et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006;49:697–706.
20. Horresh I, Poliak S, Grant S, et al. Multiple molecular interactions determine the clustering of Caspr2 and Kv1 channels in myelinated axons. J Neurosci 2008;28:14213–14222.
21. Flanagan EP, Kotsenas AL, Britton JW, et al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2015;2:e161.
22. Apiwattanakul M, McKeon A, Pittock SJ, et al. Eliminating false-positive results in serum tests for neuromuscular autoimmunity. Muscle Nerve 2010;41:702–704.
23. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715–719.
24. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
25. Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997;48:1508–1510.
26. Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590–596.
27. Low PA. Quantitation of autonomic responses. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, eds. Peripheral neuropathy. 2nd ed. Philadelphia: W. B. Saunders, 1984:1139–1166.
28. Fealey RD. The thermoregulatory sweat test. In: Low PA, ed. Clinical autonomic disorders. Boston, MA: Little, Brown and Co, 1993:225.
29. Silva J, Sharma S, Hughes B, et al. Homozygous inactivation of the LGI1 gene results in hypomyelination in the peripheral and central nervous systems. J Neurosci Res 2010;88:3328–3336.
30. Naasan G, Irani SR, Bettcher BM, et al. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 2014;71:1300–1304.
31. Arimura K, Sonoda Y, Watanabe O, et al. Isaacs' syndrome as a potassium channelopathy of the nerve. Muscle Nerve 2002;11:S55–S58.
32. Hinman JD, Peters A, Cabral H, et al. Age-related molecular reorganization at the node of Ranvier. J Comp Neurol 2006;495:351–362.
33. Elahy M, Jackaman C, Mamo JC, et al. Blood-brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing 2015;12:2.
34. Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis? Neurology 2011;76:1355–1357.
35. Horta ES, Lennon VA, Lachance DH, et al. Neural autoantibody clusters aid diagnosis of cancer. Clin Cancer Res 2014;20:3862–3869.
36. Paterson RW, Zandi MS, Armstrong R, et al. Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 2014;85:625–630.